Last A$0.04 AUD
Change Today -0.002 / -5.41%
Volume 3.0M
PRR On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
NASDAQ GM
Xetra
As of 2:10 AM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (PRR) Snapshot

Open
A$0.04
Previous Close
A$0.04
Day High
A$0.04
Day Low
A$0.04
52 Week High
07/11/13 - A$0.11
52 Week Low
10/14/13 - A$0.03
Market Cap
43.0M
Average Volume 10 Days
1.8M
EPS TTM
A$-0.01
Shares Outstanding
1.2B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRIMA BIOMED LTD (PRR)

Related News

No related news articles were found.

prima biomed ltd (PRR) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (PRR) Details

Prima BioMed Ltd., a biotechnology company, researches, develops, and commercializes licensed medical biotechnology products in Australia. Its lead product includes CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. The company is also developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. Prima BioMed Ltd. is based in Sydney, Australia.

30 Employees
Last Reported Date: 08/30/13

prima biomed ltd (PRR) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: A$312.3K
Chief Financial Officer and Chief Business Of...
Total Annual Compensation: A$213.9K
Chief Technical Officer
Total Annual Compensation: A$290.2K
General Counsel and Company Secretary
Total Annual Compensation: A$104.3K
Compensation as of Fiscal Year 2013.

prima biomed ltd (PRR) Key Developments

Prima BioMed Ltd Appoints Professors Eric Pujade-Lauraine, Christian Marth and Ignace Vergote to its Clinical Advisory Board

Prima BioMed Ltd. announced that Professors Eric Pujade-Lauraine, MD, PhD, Christian Marth, MD, PhD, and Ignace Vergote MD, PhD have joined Prima's Clinical Advisory Board to advise on the Company's development of CVac(TM) for the treatment of epithelial ovarian cancer. These researchers and clinicians join Prima's existing clinical advisory board members Jonathon Berek and Bradley Monk in the United States, Walther Kuhn in Germany, and Jeffrey Goh in Australia. Prof. Pujade-Lauraine is founder of the French GINECO Group, which is devoted to clinical research in gynecologic cancer. He is head of the Women Cancers and Clinical Research Department at Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, AP-HP. Prof. Marth is Head and Professor of the Department of Obstetrics and Gynecology, Innsbruck Medical University, and president and founder of the Austrian Association for Gynecologic Oncology (AGO), and president elect of the European Network of Gynecological Trials Group (ENGOT). Prof. Ignace Vergote is Head of the Department of Obstetrics and Gynecology and Gynecologic Oncology at the Catholic University of Leuven, Belgium. Prof. Vergote has been Chairman of the European Organization for Research and Treatment of Cancer (EORTC) Gynecologic Cancer Group from 1997 to 2003, and is currently the chairman of the Protocol committee of that group.

Prima Biomed Ltd.(ASX:PRR) dropped from S&P/ASX 300 Index

Prima Biomed Ltd.(ASX:PRR) dropped from S&P/ASX 300 Index

Prima Biomed Ltd.(ASX:PRR) dropped from S&P/ASX All Ordinaries Index

Prima Biomed Ltd.(ASX:PRR) dropped from S&P/ASX All Ordinaries Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.04 AUD -0.002

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies
 

Industry Analysis

PRR

Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.8x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit www.primabiomed.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.